Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Travere Therapeutics and keeping the price target at $47.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Travere Therapeutics’ promising future. One of the key reasons is the anticipated approval of FILSPARI for FSGS, which is expected to significantly boost the company’s revenue. The stock has shown strong performance over the past six months, reflecting positive market sentiment, and Pantginis believes this momentum will continue, especially with the upcoming PDUFA date in January 2026.
Additionally, Travere’s strategic initiatives, such as the PARASOL project, have demonstrated FILSPARI’s effectiveness in reducing proteinuria, a critical factor in kidney protection. This has been further validated by recent data, suggesting a substantial reduction in the risk of kidney failure for patients treated with FILSPARI. The company’s efforts to expand its market presence, including plans for a Japan NDA submission, also contribute to Pantginis’s optimistic outlook for Travere’s growth potential.